Evidence map›Paper›PMID 35398921›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022

Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination.

M Mizutani, H Mitsui, T Amano, Y Ogawa, N Deguchi, S Shimada, A Miwa, T Kawamura, Y Ogido

Abstract readCase ReportsLetter
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M MizutaniDepartment of Dermatology, Tokyo-kita Medical Center, Kita-ku, Japan.
H MitsuiDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Chuo, Japan.ORCID 0000-0002-1167-3038
T AmanoDepartment of Pathology, Tokyo-kita Medical Center, Kita-ku, Japan.
Y OgawaDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
N DeguchiDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
S ShimadaDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
A MiwaDepartment of Hematology, Tokyo-kita Medical Center, Kita-ku, Japan.
T KawamuraDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Y OgidoDepartment of Dermatology, Tokyo-kita Medical Center, Kita-ku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesLymphadenopathyLymphoma, Large B-Cell, DiffuseBNT162 VaccineHumansVaccinationBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID35398921
PMCPMC9114986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.